
November 17, 2017 - By Hazel Jackson
 The stock of Astrazeneca Plc (NYSE:AZN) registered a decrease of 11.84% in short interest. AZN’s total short interest was 14.88M shares in November as published by FINRA. Its down 11.84% from 16.88M shares, reported previously. With 3.58M shares average volume, it will take short sellers 4 days to cover their AZN’s short positions. The short interest to Astrazeneca Plc’s float is 0.6%. The stock increased 0.39% or $0.13 during the last trading session, reaching $33.52. About 5,300 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since November 17, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.AstraZeneca PLC is a biopharmaceutical company. The company has market cap of $83.50 billion. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 23.97 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. On Monday, September 12 the stock rating was upgraded by Jefferies to “Buy”. The stock has “Buy” rating by BMO Capital Markets on Thursday, September 14. The firm has “Buy” rating by Liberum Capital given on Friday, November 25. The stock has “Hold” rating by Leerink Swann on Thursday, July 27. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Hold” rating by HBSC on Monday, February 8. The rating was upgraded by Bryan Garnier & Cie to “Buy” on Friday, September 18. Leerink Swann maintained it with “Market Perform” rating and $34 target in Monday, May 2 report. The firm has “Neutral” rating given on Wednesday, September 14 by BNP Paribas. As per Wednesday, April 5, the company rating was downgraded by UBS. The firm has “Hold” rating given on Monday, April 10 by Jefferies.More news for AstraZeneca plc (ADR) (NYSE:AZN) were recently published by: Investorplace.com, which released: “AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success” on May 12, 2017. Investorplace.com‘s article titled: “AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment” and published on July 27, 2017 is yet another important article.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.